Equities

REMSleep Holdings Inc

RMSL:QBB

REMSleep Holdings Inc

Actions
  • Price (USD)0.0072
  • Today's Change0.000 / 2.13%
  • Shares traded1.20m
  • 1 Year change-56.36%
  • Beta0.7734
Data delayed at least 15 minutes, as of Nov 11 2024 20:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

REMSleep Holdings, Inc. is a medical technology company. The Company is focused on the development and commercialization of solutions for patients with obstructive sleep apnea. Its DeltaWave CPAP interface (the DeltaWave), which is a device to treat patients with sleep apnea. The patent-pending DeltaWave product is a nasal-pillow type interface that is designed with airflow characteristics to enable patients with sleep apnea to breathe normally. The Company’s product is manufactured by mold makers. It has molds made in China. Its target market includes sleep product distributors that distribute its product; home care dealers; private sleep labs; product end users; physicians, particularly sleep physicians; medical groups; hospitals, and medical associations, such as the American Academy of Sleep Medicine and the American Sleep Association.

  • Revenue in USD (TTM)144.88k
  • Net income in USD-1.81m
  • Incorporated2007
  • Employees6.00
  • Location
    REMSleep Holdings Inc14175 ICOT BVLD. SUITE 300CLEARWATER 33760United StatesUSA
  • Phone+1 (727) 955-4465
  • Websitehttps://www.remsleep.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Precipio Inc16.72m-3.83m9.04m51.00--0.7399--0.5407-2.68-2.6811.738.240.908917.1216.80327,843.10-20.82-44.98-27.94-58.6839.0828.80-22.90-118.070.590-192.590.0517--61.4639.6252.04--5.37--
Sigyn Therapeutics Inc0.00-3.70m9.15m5.00---------3.08-3.080.00-2.910.00----0.00-1,085.72-493.15-----------10,223.960.0247-2.09---------41.51------
ALR Technologies Inc9.49k-8.00m9.21m6.00------970.95-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Applied DNA Sciences Inc3.40m-7.52m9.64m53.00--0.1587--2.84-11.86-11.862.181.200.20926.835.6864,114.15-45.51-88.57-55.20-121.9125.0444.35-217.48-113.263.76--0.00---26.4327.92-18.73--33.80--
T2 Biosystems Inc7.16m-48.26m10.14m113.00------1.41-10.70-10.701.09-0.33910.24352.825.4163,398.23-164.01-106.01---253.03-86.96-12.60-673.67-317.930.359-12.442.00---67.75-7.2919.66---20.19--
Scientific Industries Inc10.45m-7.76m10.50m63.00--0.8992--1.00-0.9231-0.92311.171.110.73431.139.08165,942.90-54.50---62.11--45.41---74.22--3.15--0.00--------------
REMSleep Holdings Inc144.88k-1.81m10.64m6.00--18.50--73.42-0.0012-0.00120.00010.00040.081.694.75---99.82-152.40-122.32-317.98-491.08---1,246.94-2,317.521.47-43.580.1207---36.48--12.13--28.26--
QT Imaging Holdings Inc0.00-4.02m10.94m----0.5029-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
PetVivo Holdings Inc975.28k-10.11m11.19m20.00--13.43--11.48-0.6705-0.67050.0620.04170.32570.40516.3748,764.00-337.63-230.77-589.09-467.9983.6066.21-1,036.50-1,501.440.455-1,075.050.0221--5.62---25.67--23.91--
SeaStar Medical Holding Corp0.00-33.23m11.39m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Innovative Eyewear Inc1.53m-7.86m11.50m11.00--1.52--7.52-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
PAVmed Inc3.83m-67.35m11.55m107.00------3.02-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Golden Valley Development Inc0.00-92.53k11.63m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Guided Therapeutics Inc38.00k-2.39m11.68m4.00------307.30-0.0444-0.04440.0007-0.08290.02110.03658.449,500.00-120.81-136.13----42.1129.39-5,721.05-3,666.670.0679-7.58----653.8511.4524.40------
BioRegenx Inc1.29m-4.28m12.24m10.00--0.8609--9.47-0.0053-0.00530.00230.01490.1438----129,234.00-47.59---58.94--66.76---331.00--0.0533-28.810.1284---47.25---629.37------
Autonomix Medical Inc-100.00bn-100.00bn12.88m5.00--2.03----------5.50----------------------------0.1647-------674.99------
Data as of Nov 11 2024. Currency figures normalised to REMSleep Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
North Star Asset Management, Inc.as of 30 Jun 2024720.00k0.05%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.